Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914701766> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2914701766 endingPage "1469" @default.
- W2914701766 startingPage "1469" @default.
- W2914701766 abstract "1469 Objectives: To evaluate 18F-DCFPyL PET/CT as a non-invasive imaging biomarker in men with CRPC. Methods: 10 men with CRPC had 18F-DCFPyL PET/CT at baseline and after 9-14 weeks of abiraterone or enzalutemide therapy. Standard imaging (bone scan and CT) was done at baseline, after appox. 3 and 6 months of therapy. Disease extent, intra-patient tumor maximum standardized uptake value (SUVmax), therapy response by PSA and time on treatment were recorded. Men were followed for at least 12 months after enrolment. Results: Of 10 men, all had 18F-DCFPyL-avid disease. Five men with widespread disease were on treatment for 548, 399, 279, 209 and 186 days and had SUVmax 80.0, 32.4, 47.8, 19.6 and 42.7. Two men with oligometastatic disease (less than or equal to 5 lesions) were on treatment for 358 and 343 days and had SUVmax 29.7 and 5.3. The remaining 3 men (more than 5 lesions but not widespread) were on treatment for 420, 383 and 214 days and had SUVmax 17.9, 27.4 and 8.1. All men had 18F-DCFPyL-avid disease at baseline and follow-up. Further, the majority of disease sites increased in intensity on follow-up, although in several cases there were mixed interval changes. There was no significant relationship between baseline SUVmax or change in SUVmax with time on therapy. 18F-DCFPyL PET/CT suggested a more definitive estimate of baseline disease burden than standard imaging, although 2 men had non-18F-DCFPyL-avid sites of disease. Conclusions: 18F-DCFPyL PET/CT uncovers more sites of disease than standard imaging, although there is a sub-population of men with non-18F-DCFPyL-avid disease. The majority of disease sites demonstrate increasing 18F-DCFPyL following 9-14 weeks of therapy. A larger sample size is needed for confirmation." @default.
- W2914701766 created "2019-02-21" @default.
- W2914701766 creator A5002837744 @default.
- W2914701766 creator A5026175733 @default.
- W2914701766 creator A5042555322 @default.
- W2914701766 creator A5045970179 @default.
- W2914701766 creator A5049568817 @default.
- W2914701766 creator A5067187971 @default.
- W2914701766 date "2018-05-01" @default.
- W2914701766 modified "2023-09-23" @default.
- W2914701766 title "18F-DCFPyL PET/CT in Castration-Resistant Prostate Cancer (CRPC): Imaging results prior to and following abiraterone or enzalutemide therapy" @default.
- W2914701766 hasPublicationYear "2018" @default.
- W2914701766 type Work @default.
- W2914701766 sameAs 2914701766 @default.
- W2914701766 citedByCount "0" @default.
- W2914701766 crossrefType "journal-article" @default.
- W2914701766 hasAuthorship W2914701766A5002837744 @default.
- W2914701766 hasAuthorship W2914701766A5026175733 @default.
- W2914701766 hasAuthorship W2914701766A5042555322 @default.
- W2914701766 hasAuthorship W2914701766A5045970179 @default.
- W2914701766 hasAuthorship W2914701766A5049568817 @default.
- W2914701766 hasAuthorship W2914701766A5067187971 @default.
- W2914701766 hasConcept C121608353 @default.
- W2914701766 hasConcept C126322002 @default.
- W2914701766 hasConcept C126838900 @default.
- W2914701766 hasConcept C143998085 @default.
- W2914701766 hasConcept C185592680 @default.
- W2914701766 hasConcept C199374082 @default.
- W2914701766 hasConcept C2775832370 @default.
- W2914701766 hasConcept C2775842073 @default.
- W2914701766 hasConcept C2777899217 @default.
- W2914701766 hasConcept C2780192828 @default.
- W2914701766 hasConcept C2781197716 @default.
- W2914701766 hasConcept C2989005 @default.
- W2914701766 hasConcept C55493867 @default.
- W2914701766 hasConcept C71924100 @default.
- W2914701766 hasConceptScore W2914701766C121608353 @default.
- W2914701766 hasConceptScore W2914701766C126322002 @default.
- W2914701766 hasConceptScore W2914701766C126838900 @default.
- W2914701766 hasConceptScore W2914701766C143998085 @default.
- W2914701766 hasConceptScore W2914701766C185592680 @default.
- W2914701766 hasConceptScore W2914701766C199374082 @default.
- W2914701766 hasConceptScore W2914701766C2775832370 @default.
- W2914701766 hasConceptScore W2914701766C2775842073 @default.
- W2914701766 hasConceptScore W2914701766C2777899217 @default.
- W2914701766 hasConceptScore W2914701766C2780192828 @default.
- W2914701766 hasConceptScore W2914701766C2781197716 @default.
- W2914701766 hasConceptScore W2914701766C2989005 @default.
- W2914701766 hasConceptScore W2914701766C55493867 @default.
- W2914701766 hasConceptScore W2914701766C71924100 @default.
- W2914701766 hasLocation W29147017661 @default.
- W2914701766 hasOpenAccess W2914701766 @default.
- W2914701766 hasPrimaryLocation W29147017661 @default.
- W2914701766 hasRelatedWork W107086786 @default.
- W2914701766 hasRelatedWork W1981433957 @default.
- W2914701766 hasRelatedWork W2007560896 @default.
- W2914701766 hasRelatedWork W2016759796 @default.
- W2914701766 hasRelatedWork W2038428606 @default.
- W2914701766 hasRelatedWork W2085845205 @default.
- W2914701766 hasRelatedWork W2115793586 @default.
- W2914701766 hasRelatedWork W2140321408 @default.
- W2914701766 hasRelatedWork W2287184378 @default.
- W2914701766 hasRelatedWork W2316653522 @default.
- W2914701766 hasRelatedWork W2329000969 @default.
- W2914701766 hasRelatedWork W2402223943 @default.
- W2914701766 hasRelatedWork W2515807802 @default.
- W2914701766 hasRelatedWork W2530239027 @default.
- W2914701766 hasRelatedWork W2552946644 @default.
- W2914701766 hasRelatedWork W2560083478 @default.
- W2914701766 hasRelatedWork W2567033912 @default.
- W2914701766 hasRelatedWork W2626130041 @default.
- W2914701766 hasRelatedWork W2979911818 @default.
- W2914701766 hasRelatedWork W3098152784 @default.
- W2914701766 hasVolume "59" @default.
- W2914701766 isParatext "false" @default.
- W2914701766 isRetracted "false" @default.
- W2914701766 magId "2914701766" @default.
- W2914701766 workType "article" @default.